AAAAAA

   
Results: 1-16 |
Results: 16
PHASE-III STUDY COMPARING METHOTREXATE AND TACROLIMUS (PROGRAF, FK506) WITH METHOTREXATE AND CYCLOSPORINE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS AFTER HLA-IDENTICAL SIBLING BONE-MARROW TRANSPLANTATION
Authors: RATANATHARATHORN V NASH RA PRZEPIORKA D DEVINE SM KLEIN JL WEISDORF D FAY JW NADEMANEE A ANTIN JH CHRISTIANSEN NP VANDERJAGT R HERZIG RH LITZOW MR WOLFF SN LONGO WL PETERSEN FB KARANES C AVALOS B STORB R BUELL DN MAHER RM FITZSIMMONS WE WINGARD JR
Citation: V. Ratanatharathorn et al., PHASE-III STUDY COMPARING METHOTREXATE AND TACROLIMUS (PROGRAF, FK506) WITH METHOTREXATE AND CYCLOSPORINE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS AFTER HLA-IDENTICAL SIBLING BONE-MARROW TRANSPLANTATION, Blood, 92(7), 1998, pp. 2303-2314
SEQUENTIAL INTERLEUKIN-3 AND GRANULOCYTE-COLONY-STIMULATING FACTOR PRIOR TO AND FOLLOWING HIGH-DOSE ETOPOSIDE AND CYCLOPHOSPHAMIDE - A PHASE I II TRIAL/
Authors: BERNSTEIN SH FAY JP CHRISTIANSEN NP PINERO L SHAH D STEPHAN M HERZIG GP
Citation: Sh. Bernstein et al., SEQUENTIAL INTERLEUKIN-3 AND GRANULOCYTE-COLONY-STIMULATING FACTOR PRIOR TO AND FOLLOWING HIGH-DOSE ETOPOSIDE AND CYCLOPHOSPHAMIDE - A PHASE I II TRIAL/, Clinical cancer research, 3(9), 1997, pp. 1519-1526
RARE FAILURE TO ENGRAFT FOLLOWING HAPLOIDENTICAL T-CELL DEPLETED MARROW TRANSPLANTATION USING IMMUNOABLATION AND OKT3 GRAFT PURGING
Authors: HENSLEEDOWNEY PJ LEE CG HAZLETT LJ PATI AR GODDER KT ABHYANKAR SH MCGUIRK JP CHRISTIANSEN NP PARRISH RS LAMB LS GEE AP
Citation: Pj. Hensleedowney et al., RARE FAILURE TO ENGRAFT FOLLOWING HAPLOIDENTICAL T-CELL DEPLETED MARROW TRANSPLANTATION USING IMMUNOABLATION AND OKT3 GRAFT PURGING, Experimental hematology, 25(8), 1997, pp. 183-183
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) PRIMING OF HIGH-DOSE ETOPOSIDE AND CYCLOPHOSPHAMIDE - A PILOT TRIAL
Authors: BERNSTEIN SH CHRISTIANSEN NP FAY JP BROWN R HERZIG R FRANKEL S BLUMENSON L HERZIG GP
Citation: Sh. Bernstein et al., GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) PRIMING OF HIGH-DOSE ETOPOSIDE AND CYCLOPHOSPHAMIDE - A PILOT TRIAL, Experimental hematology, 24(12), 1996, pp. 1363-1368
CD34 PROGENITOR-CELL SUBSET ANALYSES IN NORMAL HUMAN BONE-MARROW AND MARROW HARVESTED AFTER INTERMEDIATE-DOSE CHEMOTHERAPY
Authors: LAUGHLIN MJ CHRISTIANSEN NP HERZIG GP BLUMENSON L BONNEY D STEWART CC
Citation: Mj. Laughlin et al., CD34 PROGENITOR-CELL SUBSET ANALYSES IN NORMAL HUMAN BONE-MARROW AND MARROW HARVESTED AFTER INTERMEDIATE-DOSE CHEMOTHERAPY, Cytometry, 26(4), 1996, pp. 235-242
DOSE-INTENSIVE CHEMOTHERAPY WITH ETOPOSIDE-CYCLOPHOSPHAMIDE FOR ADVANCED BREAST-CANCER
Authors: HERZIG RH LYNCH J CHRISTIANSEN NP FAY JW DAVIS MP HERZIG GP
Citation: Rh. Herzig et al., DOSE-INTENSIVE CHEMOTHERAPY WITH ETOPOSIDE-CYCLOPHOSPHAMIDE FOR ADVANCED BREAST-CANCER, Seminars in oncology, 23(2), 1996, pp. 28-32
PERSISTENCE OF THE AML1 ETO FUSION TRANSCRIPT IN PATIENTS TREATED WITH ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR T(8-21) LEUKEMIA/
Authors: JURLANDER J CALIGIURI MA RUUTU T BAER MR STROUT MP OBERKIRCHER AR HOFFMANN L BALL ED FREILAHR DA CHRISTIANSEN NP BLOCK AW KNUUTILA S HERZIG GP BLOOMFIELD CD
Citation: J. Jurlander et al., PERSISTENCE OF THE AML1 ETO FUSION TRANSCRIPT IN PATIENTS TREATED WITH ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR T(8-21) LEUKEMIA/, Blood, 88(6), 1996, pp. 2183-2191
MURINE MONOCLONAL-ANTIBODY DIRECTED AGAINST CD3 (OKT3) IS AN EFFECTIVE TREATMENT FOR MODERATE (GRADE-II) BUT NOT FOR SEVERE (GRADE-III OR GRADE-IV) STEROID-RESISTANT GRAFT-VERSUS-HOST DISEASE (GVHD)
Authors: SCHRIBER JR BAER MR CHRISTIANSEN NP MCCARTHY PL SLACK JL TEZCAN H WETZLER M HERZIG GP
Citation: Jr. Schriber et al., MURINE MONOCLONAL-ANTIBODY DIRECTED AGAINST CD3 (OKT3) IS AN EFFECTIVE TREATMENT FOR MODERATE (GRADE-II) BUT NOT FOR SEVERE (GRADE-III OR GRADE-IV) STEROID-RESISTANT GRAFT-VERSUS-HOST DISEASE (GVHD), Blood, 88(10), 1996, pp. 3786-3786
EFFICACY OF HEMODIALYSIS (HD) AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT)
Authors: SCHRIBER JR MOOKERJEE BK BAER MR CHRISTIANSEN NP MCCARTHY PL SLACK JL TEZCAN H WETZLER M HERZIG GP
Citation: Jr. Schriber et al., EFFICACY OF HEMODIALYSIS (HD) AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT), Blood, 88(10), 1996, pp. 460-460
A RANDOMIZED PHASE-II TRIAL COMPARING HEPARIN (HEP)+ -PROSTAGLANDIN-E1 (PG) TO PREVENT HEPATOTOXICTY (HT) FOLLOWING BONE-MARROW TRANSPLANTATION (BMT) - PRELIMINARY-RESULTS/
Authors: SCHRIBER JR MILK BJ BAER MR CHRISTIANSEN NP MCCARTHY PL SLACK JL TEZCAN H WETZLER M HERZIG GP
Citation: Jr. Schriber et al., A RANDOMIZED PHASE-II TRIAL COMPARING HEPARIN (HEP)+ -PROSTAGLANDIN-E1 (PG) TO PREVENT HEPATOTOXICTY (HT) FOLLOWING BONE-MARROW TRANSPLANTATION (BMT) - PRELIMINARY-RESULTS/, Blood, 88(10), 1996, pp. 1642-1642
PHASE-III STUDY COMPARING TACROLIMUS (PROGRAF(R), FK506) WITH CYCLOSPORINE FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS AFTER HLA-IDENTICAL SIBLING BONE-MARROW TRANSPLANTATION (BMT)
Authors: RATANATHARATHORN V NASH RA DEVINE SM PRZEPIORKA D KLEIN JL WEISDORF DJ FAY JW NADEMANEE AP ANTIN JH KARANES C AVALOS BR CHRISTIANSEN NP VANDERJAGT RH HERZIG RH LITZOW MR WOLFF SN LONGO WR PETERSEN FB BUELL DN MAHER RM FITZSIMMONS WE WINGARD JR
Citation: V. Ratanatharathorn et al., PHASE-III STUDY COMPARING TACROLIMUS (PROGRAF(R), FK506) WITH CYCLOSPORINE FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS AFTER HLA-IDENTICAL SIBLING BONE-MARROW TRANSPLANTATION (BMT), Blood, 88(10), 1996, pp. 1826-1826
BIOLOGICAL EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH UNTREATED ACUTE MYELOID-LEUKEMIA
Authors: BAER MR BERNSTEIN SH BRUNETTO VL HEINONEN K MROZEK K SWANN VL MINDERMAN H BLOCK AW PIXLEY LA CHRISTIANSEN NP FAY JW BARCOS M RUSTUM Y HERZIG GP BLOOMFIELD CD
Citation: Mr. Baer et al., BIOLOGICAL EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH UNTREATED ACUTE MYELOID-LEUKEMIA, Blood, 87(4), 1996, pp. 1484-1494
PERSISTENCE OF THE T(8-21) FUSION TRANSCRIPT FOLLOWING ALLOGENEIC (ALLO) BONE-MARROW TRANSPLANTATION (BMT) FOR ACUTE MYELOID-LEUKEMIA (AML)
Authors: JURLANDER J CALIGIURI MA STROUT MP BALL ED FREILAHR DA HOFFMANN L OBERKIRCHER AR CHRISTIANSEN NP BLOCK AW HERZIG GP BLOOMFIELD CD
Citation: J. Jurlander et al., PERSISTENCE OF THE T(8-21) FUSION TRANSCRIPT FOLLOWING ALLOGENEIC (ALLO) BONE-MARROW TRANSPLANTATION (BMT) FOR ACUTE MYELOID-LEUKEMIA (AML), Blood, 86(10), 1995, pp. 2262-2262
THIOTEPA CARBOPLATIN FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT)/
Authors: CHRISTIANSEN NP PINEIRO L COLLINS R FAY J HERZIG G
Citation: Np. Christiansen et al., THIOTEPA CARBOPLATIN FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT)/, Blood, 86(10), 1995, pp. 3753-3753
HIGH-DOSE CYTARABINE, IDARUBICIN, AND GRANULOCYTE-COLONY-STIMULATING FACTOR REMISSION INDUCTION THERAPY FOR PREVIOUSLY UNTREATED DE-NOVO AND SECONDARY ADULT ACUTE MYELOID-LEUKEMIA
Authors: BAER MR CHRISTIANSEN NP FRANKEL SR BRUNETTO VL MROZEK K BLOOMFIELD CD HERZIG GP
Citation: Mr. Baer et al., HIGH-DOSE CYTARABINE, IDARUBICIN, AND GRANULOCYTE-COLONY-STIMULATING FACTOR REMISSION INDUCTION THERAPY FOR PREVIOUSLY UNTREATED DE-NOVO AND SECONDARY ADULT ACUTE MYELOID-LEUKEMIA, Seminars in oncology, 20(6), 1993, pp. 6-12
MEASUREMENT OF LINEAGE-COMMITTED CD34-MARROW PROGENITORS IN ALLOGENEIC TRANSPLANTATION( BONE)
Authors: LAUGHLIN M CHRISTIANSEN NP STEWART CC NETTLETON A BONNEY D HERZIG GP
Citation: M. Laughlin et al., MEASUREMENT OF LINEAGE-COMMITTED CD34-MARROW PROGENITORS IN ALLOGENEIC TRANSPLANTATION( BONE), Blood, 82(10), 1993, pp. 10000650-10000650
Risultati: 1-16 |